Ahmed, H. (2005). Principles and reactions of protein extraction, purification, and characterization: CRC press New York.
Ansari, A, Gheysarzadeh, A, Mofid, MR. (2017).The interaction of insulin-like growth factor binding protein 3 (IGFBP-3) in insulin-like growth factor (IGF)-independent system.J. Isfahan Med. School, 35(451):1452-1461.
Ashton, JC. (2015). Drug Combination Studies and Their Synergy Quantification Using the Chou–Talalay Method.Cancer Res., 75(11):400-446.
Brown, RL, de Souza, JA, Cohen, EE. (2011). Thyroid cancer: burden of illness and management of disease. J. Cancer, 2:193-199.
Brown, KK, Toker, A. (2015). The phosphoinositide 3-kinase pathway and therapy resistance in cancer.F1000prime Rep., 7:13-21.
del Alcazar, CRG, Hardebeck, MC, Mukherjee, B, Tomimatsu, N, Gao, X, Yan, J, Xie, XJ, Bachoo, R, Li, L, Habib, AA, Burma, S. (2014). Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin. Cancer Res., 20(5):1235-1248.
Elkabets, M, Vora, S, Juric, D, Morse, N, Mino-Kenudson, M, Muranen, T, Tao, J, Campos, AB, Rodon, J, Ibrahim, YH, Serra, V, Rodrik-Outmezguine, V, Hazra, S, Singh, S, Kim, P, Quadt, C, Liu, M, Huang, A, Rosen, N, Engelman, JA, Scaltriti, M, Baselga, J. (2013). mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci. Translat. Med., 5(196):1-28.
Gheysarzadeh, A, Yazdanparast, R. (2012).Inhibition of H2O2-induced cell death through FOXO1 modulation by EUK-172 in SK-N-MC cells.Eur. J. Pharmacol., 697(1):47-52.
Gheysarzadeh, A, Ansari, A, Emami, MH, Razavi, AE, Mofid, MR. (2019). Over-expression of low-density lipoprotein receptor-related Protein-1 is associated with poor prognosis and invasion in pancreatic ductal adenocarcinoma. Pancreatology, 19:429-435.
Gheysarzadeh, A, Bakhtiari, H, Ansari, A, EmamiRazavi, A, Emami, MH, Mofid, MR. (2019).The insulin‐like growth factor binding protein‐3 and its death receptor in pancreatic ductal adenocarcinoma poor prognosis. J. Cell. Physiol., 234:23537-23546.
Gheysarzadeh, A, Sadeghifard, N, Afraidooni, L, Pooyan, F, Mofid, MR, Valadbeigi, H, Bakhtiari, H, Keikhavani, S. (2018). Serum-based microRNA biomarkers for major depression: MiR-16, miR-135a, and miR-1202. J. Res. Med. Sci., 23:69-81.
Hamzeloo-Moghadam, M, Aghaei, M, Fallahian, F, Jafari, SM, Dolati, M, Abdolmohammadi, MH, Hajiahmadi, S, Esmaeili, S. (2015). Britannin, a sesquiterpene lactone, inhibits proliferation and induces apoptosis through the mitochondrial signaling pathway in human breast cancer cells. Tumor Biology., 36(2):1191-1198.
Hedinger, C, Dillwyn Williams, E, Sobin, LH. (1989). The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer, 63(5):908-911.
Hou, P, Liu, D, Shan, Y, Hu, S, Studeman, K, Condouris, S, Wang, Y, Trink, A, El-Naggar, AK, Tallini, G, Vasko, V, Xing, M. (2007).Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.Clin. Cancer Res., 13(4):1161-1170.
Jafari, E, Gheysarzadeh, A, Mahnam, K, Shahmohammadi, R, Ansari, A, Bakhtyari, H, Mofid, MR. (2018). In silico interaction of insulin-like growth factor binding protein 3 with insulin-like growth factor 1. Res. Pharm. Sci., 13(4):332-342.
Lee, HJ, Lee, WK, Kang, CW, Ku, CR, Cho, YH, Lee, EJ. (2018). A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer. Cancer Lett., 417:131-140.
Lopes-Ventura, S, Pojo, M, Matias, A, Moura,M, Marques, I, Leite, V, Cavaco, BM. (2018). The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.J. Endocrinol. Investigat.,42(5):527-540.
Maleki, F, Noorkhoda, S, Halabian, R, Behzadi, E, Fooladi, AAI. (2018). The Role of Epidermal Growth Factor Receptor in Cancer and their Application for New Targeted Cancer Therapy. J. Clin. Diag. Res., 12(6):XE01-XE06.
Maleki, F, Sadeghifard, N, Hosseini, HM, Bakhtiyari, S, Goleij, Z, Behzadi, E, Sedighian, H, Imani Fooladi, AA. (2019). Growth-inhibitory effects of TGFαL3-SEB chimeric protein on colon cancer cell line.Biomed.Pharmac.,110:190-196.
Markman, B, Tabernero, J, Krop, I, Shapiro, G, Siu, L, Chen, LC, Mita, M, Melendez Cuero, M, Stutvoet, S, Birle, D, Anak, O, Hackl, W, Baselga, J. (2012). Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann. oncol., 23(9):2399-2408.
Mazzaferri, EL, Kloos, RT. (2001). Current approaches to primary therapy for papillary and follicular thyroid cancer. J. Clin. Endocrinol.Metabolism., 86(4):1447-1463.
Nix, P, Nicolaides, A, Coatesworth, A. (2005). Thyroid cancer review 1: presentation and investigation of thyroid cancer. Int. J. Clin. Pract., 59(11):1340-1344.
Nozhat, Z, Mohammadi-Yeganeh, S, Azizi, F, Zarkesh, M, Hedayati, M. (2018). Effects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines. DARU J. Pharmac. Sci., 26(2):93-103.
Peyton, J, RodonAhnert, J, Burris, H, Britten, C, Chen, L, Tabernero, J, Duval, V, Rouyrre, N, Silva, AP, Quadt, C, Baselga, J. (2011).A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. J.Clin. Oncol., 29(15_suppl):3066-3066.
Pojo, M, Lopes-Ventura, S, Matias, A, Leite, V, Cavaco, B. (2017). Inhibition of hRAS and CDK4/6 leads to an antiproliferative activity, blocks cell cycle and induces cell death in anaplastic thyroid cancer cell lines. 49, GP126, DOI: 10.1530/endoabs.49.GP126
Pópulo, H, Lopes, JM, Soares, P. (2012). The mTORsignalling pathway in human cancer.Int. J. Molecul. Sci., 13(2):1886-918.
Rahib, L, Smith, BD, Aizenberg, R, Rosenzweig, AB, Fleshman, JM, Matrisian, LM. (2014). Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res., 74(11):2913-2921.
Tagliaferri, L, Gobitti, C, Colloca, GF, Boldrini, L, Farina, E, Furlan, C, Paiar, F, Vianello, F, Basso, M, Cerizza, L, Monari, F, Simontacchi, G, Gambacorta, MA, Lenkowicz, J, Dinapoli, N, Lanzotti, V, Mazzarotto, R, Russi, E, Mangoni, M. (2018). A new standardized data collection system for interdisciplinary thyroid cancer management: Thyroid COBRA. Eur. J. Int. Med., 53:73-78.
Vasko, V, Saji, M, Hardy, E, Kruhlak, M, Larin, A, Savchenko, V, Miyakawa, M, Isozaki, O, Murakami, H, Tsushima, T, Burman, KD, De Micco, C, Ringel, MD. (2004). Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J. Med. Genet., 41(3):161-170.
Vivanco, I, Sawyers, CL. (2002).The phosphatidylinositol 3-kinase–AKT pathway in human cancer.Nat. Rev. Cancer, 2(7):489-501.
Wartofsky, L, Van Nostrand, D. (2016). Thyroid cancer: a comprehensive guide to clinical management: Springer.
Wu, P, Nielsen, TE, Clausen, MH. (2015). FDA-approved small-molecule kinase inhibitors.Trend.Pharmacol. Sci., 36(7):422-439.
Zarkesh, M, Zadeh-Vakili, A, Akbarzadeh, M, Fanaei, SA, Hedayati, M, Azizi, F. (2018).The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer. BMC Cancer, 18(1):1199-1210.